Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9827129 | 0.82 | DYRK1A (0.36) | NPC1MAPTRAB9AKMT2A | |
| SCHEMBL20489428 | 0.81 | — | — | |
| SCHEMBL2499122 | 0.78 | TRPM8 (0.46) | TRPM8NPC1MAPTRAB9AKMT2A | |
| SCHEMBL20489652 | 0.77 | TRPM8 (0.39) | TRPM8NPC1MAPTRAB9AKMT2A | |
| SCHEMBL20489697 | 0.76 | POLB (0.40) | NPC1MAPTRAB9AKMT2ATP53 | |
| SCHEMBL21206864 | 0.74 | TRPM8 (0.42) | TRPM8NPC1MAPTRAB9AKMT2A | |
| SCHEMBL20489625 | 0.74 | GLS (0.40) | NPC1MAPTRAB9AKMT2A | |
| SCHEMBL20489609 | 0.72 | RAB9A (0.41) | NPC1MAPTRAB9AKMT2ATP53 | |
| SCHEMBL21206872 | 0.71 | TRPM8 (0.40) | TRPM8NPC1MAPTRAB9AKMT2A | |
| SCHEMBL12428741 | 0.71 | TRPM8 (0.61) | TRPM8NPC1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705294-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | Aurigene Oncology Limited (IN) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228132-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-11-07 | — | — | WO | disclosed |
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | TRPM8 2795/4885NPC1 730/4885MAPT 2348/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | TRPM8 2820/4885NPC1 707/4885MAPT 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.